Exelixis, Inc.

NasdaqGS:EXEL Stock Report

Market Cap: US$10.4b

Exelixis Management

Management criteria checks 4/4

Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 15.33 years. total yearly compensation is $12.73M, comprised of 9.8% salary and 90.2% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth $76.26M. The average tenure of the management team and the board of directors is 10.3 years and 8.4 years respectively.

Key information

Mike Morrissey

Chief executive officer

US$12.7m

Total compensation

CEO salary percentage9.84%
CEO tenure15.3yrs
CEO ownership0.7%
Management average tenure10.3yrs
Board average tenure8.4yrs

Recent management updates

Recent updates

Exelixis: Digesting The Big STELLAR-303 Update And The Road Ahead

Oct 21

With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case

May 09
With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case

Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings

Apr 16
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings

Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts

Mar 13

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Feb 21
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Jan 09

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31
User avatar

Cabozantinib's Momentum And Tactical Growth Amid Market Challenges Propel Biotech Innovation

Strong commercial performance of the cabozantinib franchise, indicating sustained revenue growth through market penetration and diversification into new indications.

Exelixis Comes Up Aces

Aug 08

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

CEO Compensation Analysis

How has Mike Morrissey's remuneration changed compared to Exelixis's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

US$602m

Mar 31 2025n/an/a

US$644m

Dec 31 2024n/an/a

US$521m

Sep 30 2024n/an/a

US$467m

Jun 30 2024n/an/a

US$350m

Mar 31 2024n/an/a

US$205m

Dec 31 2023n/an/a

US$208m

Sep 30 2023n/an/a

US$92m

Jun 30 2023n/an/a

US$164m

Mar 31 2023n/an/a

US$154m

Dec 31 2022US$17mUS$1m

US$182m

Sep 30 2022n/an/a

US$308m

Jun 30 2022n/an/a

US$273m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$8mUS$1m

US$231m

Sep 30 2021n/an/a

US$164m

Jun 30 2021n/an/a

US$94m

Mar 31 2021n/an/a

US$65m

Dec 31 2020n/an/a

US$112m

Sep 30 2020n/an/a

US$152m

Jun 30 2020n/an/a

US$282m

Mar 31 2020n/an/a

US$294m

Dec 31 2019n/an/a

US$321m

Sep 30 2019n/an/a

US$612m

Jun 30 2019n/an/a

US$642m

Mar 31 2019n/an/a

US$650m

Dec 31 2018n/an/a

US$690m

Compensation vs Market: Mike's total compensation ($USD12.73M) is about average for companies of similar size in the US market ($USD13.47M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Morrissey (64 yo)

15.3yrs
Tenure
US$12,732,048
Compensation

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Leadership Team

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Independent Chair of the Board30.9yrsUS$542.60k0.47%
$ 48.7m
Michael Morrissey
CEO, President & Director15.3yrsUS$12.73m0.73%
$ 76.3m
Christopher Senner
Executive VP & CFO10.3yrsUS$4.68m0.20%
$ 21.3m
Jeffrey Hessekiel
Executive VP & General Counsel11.8yrsUS$3.74m0.12%
$ 12.5m
Dana Aftab
Executive Vice President of Research & Developmentless than a yearUS$3.62m0.11%
$ 11.1m
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations8.9yrsno datano data
Anne Champsaur
Senior Vice President of Drug Safety10.6yrsno datano data
William Berg
Senior Vice President of Medical Affairs10.2yrsno datano data
Patrick Haley
Executive Vice President of Commercial8.9yrsUS$4.65m0.027%
$ 2.8m
Stefan Krauss
VP & Head of Business Developmentno datano datano data
Andrew Peters
Senior Vice President of Strategyno datano datano data
Deborah Burke
Senior VP of Finance & Controller10.3yrsUS$951.13kno data
10.3yrs
Average Tenure
62yo
Average Age

Experienced Management: EXEL's management team is seasoned and experienced (10.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stelios Papadopoulos
Co-Founder & Independent Chair of the Board30.9yrsUS$542.60k0.47%
$ 48.7m
Michael Morrissey
CEO, President & Director15.3yrsUS$12.73m0.73%
$ 76.3m
Jack Wyszomierski
Independent Director21.8yrsUS$510.60k0.13%
$ 13.5m
George Poste
Independent Director21.3yrsUS$505.60k0.056%
$ 5.8m
Charles Sawyers
Member of the Scientific Advisory Boardno datano datano data
Ronald Evans
Member of the Scientific Advisory Boardno datano datano data
Sue Eckhardt
Independent Director1.8yrsUS$1.16m0%
$ 0
Mary Beckerle
Independent Director1.8yrsUS$1.16m0%
$ 0
Julie Smith
Independent Director9.2yrsUS$507.80k0.00028%
$ 29.1k
Maria Freire
Independent Director7.6yrsUS$511.60k0.027%
$ 2.8m
Robert Oliver
Independent Director2.5yrsUS$492.60k0.00039%
$ 40.6k
Tomas Heyman
Independent Director2.5yrsUS$499.10k0%
$ 0
8.4yrs
Average Tenure
69yo
Average Age

Experienced Board: EXEL's board of directors are considered experienced (8.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 03:48
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exelixis, Inc. is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Jason Matthew GerberryBofA Global Research